Advanced search
Publication Cover
Current Medical Research and Opinion Volume 28, 2012 - Issue 12
Submit an article Journal homepage
436
Views
8
CrossRef citations to date
0
Altmetric
Oncology: Original Article

Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials

Yongqing WangResearch Division of Clinical Pharmacology, the First Affiliated Hospital, Nanjing Medical University NanjingChina
,
Haiwei YangClinical Experiment Center, the First Affiliated Hospital, Nanjing Medical University NanjingChina
,
Ji-Fu WeiResearch Division of Clinical Pharmacology, the First Affiliated Hospital, Nanjing Medical University NanjingChinaCorrespondence[email protected]
&
Ling MengResearch Division of Clinical Pharmacology, the First Affiliated Hospital, Nanjing Medical University NanjingChina
Pages 1911-1919 | Accepted 07 Nov 2012, Published online: 27 Nov 2012

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Nanxin Li, Yanni Hao, Andrew Kageleiry, Miranda Peeples, Anna Fang, Valerie Koo, Eric Q. Wu & Annie Guérin. (2016) Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US. Current Medical Research and Opinion 32:2, pages 385-394.
Read now
Alberto Bongiovanni, Nada Riva, Sebastiano Calpona, Marianna Ricci, Erica Gunelli, Chiara Liverani, Federico La Manna, Alessandro De Vita, Manuela Monti, Stefano Severi, Federica Pieri, Elena Amadori, Riccardo Galassi, Davide Cavaliere, Alberto Zaccaroni, Andreas Tartaglia, Veronica Lunedei, Andrea Gardini, Laura Mercatali, Dino Amadori & Toni Ibrahim. (2014) Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature. OncoTargets and Therapy 7, pages 1919-1926.
Read now

Articles from other publishers (6)

A.H. Awada, V. Boni, V. Moreno, P. Aftimos, C. Kahatt, X.E. Luepke-Estefan, M. Siguero, C. Fernandez-Teruel, M. Cullell-Young & J. Tabernero. (2022) Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer. ESMO Open 7:6, pages 100651.
Crossref
Siao-Nge Hoon, Peter K H Lau, Alison M White, Max K Bulsara, Patricia D Banks & Andrew D Redfern. (2021) Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer. Cochrane Database of Systematic Reviews 2021:5.
Crossref
A. G. J. van Rossum, P. C. Schouten, K. E. Weber, V. Nekljudova, C. Denkert, C. Solbach, C. H. Köhne, C. Thomssen, H. Forstbauer, G. Hoffmann, A. Kohls, S. Schmatloch, C. Schem, G. von Minckwitz, T. Karn, V. J. Möbus, S. C. Linn, S. Loibl & F. Marmé. (2017) BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial. Breast Cancer Research and Treatment 166:3, pages 775-785.
Crossref
Ze-Chun Zhang, Qi-Ni Xu, Sui-Ling Lin & Xu-Yuan Li. (2016) Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials. PLOS ONE 11:10, pages e0164663.
Crossref
Yanni Hao, Nanxin Li, Anna P. Fang, Valerie Koo, Miranda Peeples, Andrew Kageleiry, Eric Q. Wu & Annie Guérin. (2016) Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2− Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy. Advances in Therapy 33:6, pages 983-997.
Crossref
Xiaohui Zhang, Yidong Zhou, Feng Mao, Yan Lin, Jinghong Guan & Qiang Sun. (2015) Efficacy and safety of pirarubicin plus capecitabine versus pirarubicin plus cyclophosphamide in Chinese node-negative breast cancer patients: a 4-year open-label, randomized, controlled study. Medical Oncology 32:10.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.